[Update of the treatment of multiple sclerosis].
Recently a lot of new therapeutic agents for multiple sclerosis (MS) have been developed and the guidelines for treatment have revised. In particular, fingolimod which was placed on the market at the end of 2011 has been focused because of the first oral drug for MS. Novel therapeutic agents for MS can be divided into the following three patterns: (1) newly developed drugs, (2) the induction of drugs that are already used in the U.S. and Europe, (3) expanded indications for drugs that have been approved in other diseases. The new drug is in demand for stronger therapeutic effect and more convenient drug administration.